The Department of Health and Human Services (DHHS) Sickle Cell Disease (SCD) Initiative: Increasing Access and Improving Care
Susan B. Shurin(National Institutes of Health), Bonnie Strickland(Health Resources and Services Administration), Garth Graham(Office of Minority Health), Hani K. Atrash(Unknown), Peter Lurie(Center for Science in the Public Interest (United States)), Echezona E. Ezeanolue(University of Nigeria), Marsha D. Lillie-Hampton, Coleen Boyle, Ann T. Farrell(Center for Drug Evaluation and Research), Denise Dougherty(Office of Extramural Research), Randy L. Brown(Health Resources and Services Administration), Sara Copeland(Health Resources and Services Administration), Althea M. Grant(Centers for Disease Control and Prevention), Michael Millman(Office of the Assistant Secretary for Planning and Evaluation), Janet L. Collins(National Center for Chronic Disease Prevention and Health Promotion), Dora L. Hughes(Office of the Secretary of Health and Human Services)
Cited by 0
Related Papers
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy
|JAMA|2016|781
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
|The Oncologist|2003|629
FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension
|The Oncologist|2005|488
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
|Clinical Cancer Research|2006|466